Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data

Movement Disorders

Volumn 25, Issue 4, 2010, Pages 474-480

  Davis, Keith L ^a   Edin, Heather M ^b   Allen, Jeffery K ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Claims data; Costs; Nonadherence; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG PRESCRIPTIONS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH, REIMBURSEMENT; LEVODOPA; MALE; MANAGED CARE PROGRAMS; NORTH CAROLINA; PARKINSON DISEASE; PATIENT COMPLIANCE; PREVALENCE;

EID: 77949498887     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22999     Document Type: Article

References (31)

1. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: RB Haynes, WD Taylor, DL Sackett, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p11-22.
2. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288: 2880-2883.
3. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-268.
4. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54 (Suppl 1):557-560.
5. Haynes RB, Dantes R. Patient compliance in the design and interpretation of clinical trials. Control Clin Trials 1987;8:12-19.
6. Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, Dorian P. Poor compliance to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Psychosom Med 1999;61:566-575.
7. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-280.
8. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-2335.
9. Breen R, Thornhill JT. Noncomplianceadherence with medication for psychiatric disorders. CNS Drugs 1998;9:457-471.
10. Smith M. The cost of noncompliance and the capacity of improve compliance to reduce health care expenditures. In: Improving Medication Compliance: Proceedings of a Symposium. Zona G, ed. VA: National Pharmaceutical Council; 1985. p 35-42.
11. Iskedjian M, Addis A, Einarson T. Estimating the cost of hospital admissions due to patient noncompliance in Ontario Canada. Pharmacoepidemiol Drug Saf 1998;7:S92.
12. Chaudhuri KR, Taurah LS, MacMahon DG, et al. PD LIFE-a prospective mutli-centre longitudinal audit of quality of life in Parkinson's disease across the UK. J Neurol Neurosurg Psychiatry 2004;75:516.
13. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005;20:1397-1404.
14. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-517.
15. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507.
16. Caron HS, Roth HP. Patients' cooperation with a medical regimen. JAMA 1968;203:922-926.
17. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996;28:154-158.
18. Kulkarni AS, Balkrishnan R, Anderson RT, et al. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2007;23:359-365.
19. Nausieda PA, Pfeiffer RF, Tagliati M, et al. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 2005;27: 58-63.
20. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing complianceadherence with antiepileptic drug regimes. Seizure 1997;6:87-93.
21. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
22. Leoni O, Martignoni E, Cosentino M, et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 2002;11:149-157.
23. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574.
24. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11: 449-457.
25. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001;19:1185-1197.
26. Elm JJ, Kamp C, Tilley BC, et al. Self-reported adherence versus pill count in Parkinson's disease: then NET-PD experience. Mov Disord 2007;22:822-827.
27. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a1 5-year levodopa-controlled study-056 study group. Mov Disord 1998;13:39-45.
28. Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Psychiatry 1997;50:105-116.
29. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
30. Noyes K, Liu H, Li Y, et al. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 2006;21:362-372.
31. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454.